Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cerlapirdine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 known ✓ | P50406 | 13/20 | 0.71 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 2/20 | 0.43 |
| ▸ | TOP2A | P11388 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cerlapirdine SCHEMBL29375645 | 1.00 | HTR6 (0.71) | HTR6PDGFRBPDGFRAHTR1BTOP2A | |
| Cerlapirdine SCHEMBL3531794 | 0.99 | HTR6 (0.70) | HTR6PDGFRBPDGFRAHTR1BTOP2A | |
| SCHEMBL3534211 | 0.97 | HTR6 (0.67) | HTR6PDGFRBPDGFRAHTR1BTOP2A | |
| SCHEMBL3531307 | 0.95 | HTR6 (0.64) | HTR6PDGFRBPDGFRAHTR1BTOP2A | |
| SCHEMBL3533745 | 0.92 | HTR6 (0.60) | HTR6PDGFRBPDGFRAHTR2A | |
| Hydrochloric Acid SCHEMBL3528991 | 0.91 | HTR6 (0.59) | HTR6PDGFRBPDGFRAHTR2A | |
| SCHEMBL3529039 | 0.90 | HTR6 (0.58) | HTR6PTPN1 | |
| Hydrochloric Acid SCHEMBL3534727 | 0.90 | HTR6 (0.58) | HTR6PTPN1 | |
| SCHEMBL3532505 | 0.89 | HTR6 (0.56) | HTR6HTR1BHTR2A | |
| SCHEMBL3533813 | 0.88 | HTR6 (0.56) | HTR6HTR1BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723329-B2 | Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-05-25 | — | — | US | claimed |
| EP-1971334-A2 | COMBINATION OF ACHE INHIBITOR AND 5-HT6 ANTAGONIST FOR THE TREATMENT OF COGNITIVE DYSFUNCTION | Wyeth a Corporation of the State of Delaware (US) | 2008-09-24 | — | — | EP | claimed |
| EP-1931640-A2 | SUBSTITUTED-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth a Corporation of the State of Delaware (US) | 2008-06-18 | — | — | EP | claimed |
| WO-2007087151-A2 | COMBINATION OF ACHE INHIBITOR AND 5-HT6 ANTAGONIST FOR THE TREATMENT OF COGNITIVE DYSFUNCTION | WYETH (US) | 2007-08-02 | — | — | WO | claimed |
| US-20070167431-A1 | Method for the treatment of cognitive dysfunction | WYETH (US) | 2007-07-19 | — | — | US | claimed |
| WO-2007021711-A2 | SUBSTITUTED-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2007-02-22 | — | — | WO | claimed |
| US-20070037802-A1 | such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders | WYETH (US) | 2007-02-15 | — | — | US | claimed |
| US-10449144-B2 | WT1 peptide cancer vaccine composition for transdermal administration | NITTO DENKO CORPORATION (JP) | 2019-10-22 | — | — | US | disclosed |
| US-10206985-B2 | WT1 peptide cancer vaccine composition for mucosal administration | NITTO DENKO CORPORATION (JP) | 2019-02-19 | — | — | US | disclosed |
| US-10195258-B2 | Tape preparation of WT1 peptide cancer vaccine for transdermal administration | NITTO DENKO CORPORATION (JP) | 2019-02-05 | — | — | US | disclosed |
| EP-3027613-B1 | PYRROLOQUINOLINE DERIVATIVES AS 5-HT6 ANTAGONISTS, PREPARATION METHOD AND USE THEREOF | UNIV JAGIELLONSKI (PL) | 2018-03-28 | — | — | EP | disclosed |
| US-20170239237-A1 | PYRROLOQUINOLINE DERIVATIVES AS 5-HT6 ANTAGONISTS, PREPARATION METHOD AND USE THEREOF | UNIVERSITE DE MONTPELLIER (FR) | 2017-08-24 | — | — | US | disclosed |
| US-20170239237-A1 | PYRROLOQUINOLINE DERIVATIVES AS 5-HT6 ANTAGONISTS, PREPARATION METHOD AND USE THEREOF | UNIVERSITE DE MONTPELLIER (FR) | 2017-08-24 | — | — | US | disclosed |
| WO-2007087151-A2 | COMBINATION OF ACHE INHIBITOR AND 5-HT6 ANTAGONIST FOR THE TREATMENT OF COGNITIVE DYSFUNCTION | WYETH (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20070167431-A1 | Method for the treatment of cognitive dysfunction | WYETH (US) | 2007-07-19 | — | — | US | disclosed |
| WO-2007021711-A2 | SUBSTITUTED-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007021711-A2 | SUBSTITUTED-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037802-A1 | such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders | WYETH (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037802-A1 | such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders | WYETH (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037802-A1 | such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders | WYETH (US) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10206985-B2 | WT1 peptide cancer vaccine composition for mucosal administration | MUC1, TAP1, MICA | HTR6 3588/4885PDGFRB 3545/4885PDGFRA 3924/4885 |
| US-10449144-B2 | WT1 peptide cancer vaccine composition for transdermal administration | TAP1, TAP2, MICA | HTR6 3627/4885PDGFRB 3618/4885PDGFRA 4066/4885 |
| US-20070167431-A1 | Method for the treatment of cognitive dysfunction | ACHE, BCHE, HTR6 | HTR6 3/4885PDGFRB 4088/4885PDGFRA 4424/4885 |
| US-20070037802-A1 | such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders | HTR6, TPH1, HTR1A | HTR6 1/4885PDGFRB 2128/4885PDGFRA 1779/4885 |
| US-10195258-B2 | Tape preparation of WT1 peptide cancer vaccine for transdermal administration | TAP1, TAP2, MICA | HTR6 4312/4885PDGFRB 4218/4885PDGFRA 4324/4885 |
| US-20170239237-A1 | PYRROLOQUINOLINE DERIVATIVES AS 5-HT6 ANTAGONISTS, PREPARATION METHOD AND USE THEREOF | HTR6, HTR2C, HTR3B | HTR6 1/4885PDGFRB 502/4885PDGFRA 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.